Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

被引:507
作者
Cretney, E
Takeda, K
Yagita, H
Glaccum, M
Peschon, JJ
Smyth, MJ
机构
[1] Peter MacCallum Canc Inst, Sir Donald & Lady Trescowthick Lab, Canc Immunol Program, Melbourne, Vic 8006, Australia
[2] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan
[3] Immunex Corp, Seattle, WA USA
关键词
D O I
10.4049/jimmunol.168.3.1356
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously implicated TNF-related apoptosis-inducing ligand (TRAIL) in innate immune surveillance against tumor development. In this study, we describe the use of TRAIL gene-targeted mice to demonstrate the key role of TRAIL in suppressing tumor initiation and metastasis. Liver and spleen mononuclear cells from TRAIL gene-targeted mice were devoid of TRAIL expression and TRAIL-mediated cytotoxicity. TRAIL gene-targeted mice were more susceptible to experimental and spontaneous tumor metastasis, and the immunotherapeutic value of alpha-galactosylceramide was diminished in TRAIL gene-targeted mice. TRAIL gene-targeted mice were also more sensitive to the chemical carcinogen methyleholanthrene. These results substantiated TRAIL as an important natural effector molecule used in the host defense against transformed cells.
引用
收藏
页码:1356 / 1361
页数:6
相关论文
共 30 条
  • [1] Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi, A
    Pai, RC
    Fong, S
    Leung, S
    Lawrence, DA
    Masters, SA
    Blackie, C
    Chang, L
    McMurtrey, AE
    Hebert, A
    DeForge, L
    Koumenis, IL
    Lewis, D
    Harris, L
    Bussiere, J
    Koeppen, H
    Shahrokh, Z
    Schwall, RH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 155 - 162
  • [2] ASLAKSON CJ, 1992, CANCER RES, V52, P1399
  • [3] Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice
    Boggio, K
    Nicoletti, G
    Di Carlo, E
    Cavallo, F
    Landuzzi, L
    Melani, C
    Giovarelli, M
    Rossi, I
    Nanni, P
    De Giovanni, C
    Bouchard, P
    Wolf, S
    Modesti, A
    Musiani, P
    Lollini, PL
    Colombo, MP
    Forni, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (03) : 589 - 596
  • [4] Davis JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO
  • [5] 2-1
  • [6] The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    Degli-Esposti, MA
    Dougall, WC
    Smolak, PJ
    Waugh, JY
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1997, 7 (06) : 813 - 820
  • [7] Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis
    Hilliard, B
    Wilmen, A
    Seidel, C
    Liu, TST
    Göke, R
    Chen, YH
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (02) : 1314 - 1319
  • [8] Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type IIFNs
    Kayagaki, N
    Yamaguchi, N
    Nakayama, M
    Eto, H
    Okumura, K
    Yagita, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (09) : 1451 - 1460
  • [9] Kayagaki N, 1999, J IMMUNOL, V163, P1906
  • [10] Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
    Lin, PN
    Buxton, JA
    Acheson, A
    Radziejewski, C
    Maisonpierre, PC
    Yancopoulos, GD
    Channon, KM
    Hale, LP
    Dewhirst, MW
    George, SE
    Peters, KG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8829 - 8834